Vera Therapeutics (VERA) Total Debt (2021 - 2026)
Vera Therapeutics' (VERA) quarterly Total Debt came in at $75.0 million in Q1 2026, up 50.06% YoY from $50.0 million in Q1 2025, and little changed on a QoQ basis from $74.8 million in Q4 2025.
Vera Therapeutics (VERA) Total Debt (2021 - 2026) Analysis & Trends
Vera Therapeutics (VERA) has 6 years of Total Debt data on file, last reported at $75.0 million in Q1 2026.
- Quarterly Total Debt rose 50.06% year-over-year to $75.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.0 million (up 50.06% YoY) and the FY2025 annual result came in at $74.8 million, up 49.68% from the prior year.
- Total Debt was little changed at $75.0 million in Q1 2026, from $74.8 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $75.0 million in Q1 2026 to a low of $6.0 million in Q3 2022.
- A 5-year average of $42.6 million and a median of $50.0 million in 2024 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2022 — Total Debt soared 500.6% — and 2025, when it decreased 0.13%.
- Tracing VERA's Total Debt over 5 years: stood at $27.8 million in 2022, then surged by 79.54% to $49.9 million in 2023, then grew by 0.25% to $50.0 million in 2024, then surged by 49.68% to $74.8 million in 2025, then climbed by 0.26% to $75.0 million in 2026.
- The last three Total Debt figures came in at $75.0 million (Q1 2026), $74.8 million (Q4 2025), and $75.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Vera Therapeutics | 2.28 Bn | 2.28 Bn | - | 75.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.23 Mn |
| Mar 31, 2026 | 75.03 Mn |
| Dec 31, 2025 | 74.84 Mn |
| Sep 30, 2025 | 75.00 Mn |
| Jun 30, 2025 | 74.46 Mn |
| Mar 31, 2025 | 50.00 Mn |
| Dec 31, 2024 | 50.00 Mn |
| Sep 30, 2024 | 50.00 Mn |
| Jun 30, 2024 | 50.00 Mn |
| Mar 31, 2024 | 50.07 Mn |
| Dec 31, 2023 | 49.88 Mn |
| Sep 30, 2023 | 25.00 Mn |
| Jun 30, 2023 | 24.96 Mn |
| Mar 31, 2023 | 28.07 Mn |
| Dec 31, 2022 | 27.78 Mn |
| Sep 30, 2022 | 5.97 Mn |
| Jun 30, 2022 | 6.70 Mn |
| Mar 31, 2022 | 6.64 Mn |
| Dec 31, 2021 | 6.02 Mn |
| Sep 30, 2021 | 994,000.00 |